Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Key claim: A phase II trial is evaluating whether ascorbic acid plus combination chemotherapy can improve killing of cancer cells in relapsed/refractory lymphoma, CCUS, and CMML by sensitizing cells to chemotherapy.
Abstract
This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may kill more cancer cells.
Arms A, B, C, and D are closed to enrollment.
Why this matters
A phase II trial is evaluating whether ascorbic acid plus combination chemotherapy can improve killing of cancer cells in relapsed/refractory lymphoma, CCUS, and CMML by sensitizing cells to chemotherapy.